Our Team

Professionals

Alon
Chen

Scientific Vision

Ilana
Fogelman

Chief executive officer

Michel Ben Horovitz

Chief Financial Officer

Sharon Manashirov

Head of Science

Andrés
Montefeltro

Head of Delivery Platform Technology

Ruben
Pavia

Staff scientist

Alon Chen

Scientific Vision
Share on linkedin

Professor Alon Chen is the President of Weizmann Institute of Science, Rehovot, Israel and a Director at the Max Planck Institute of Psychiatry, Munich Germany. Prof. Chen also serves as the Head of the Max Planck Society – Weizmann Institute of Science Laboratory for Experimental Neuropsychiatry and Behavioral Neurogenetics. Prof. Chen’s research focuses on the Neurobiology of Stress, particularly the mechanisms by which the brain is regulating the response to stressful challenges and how this response is linked to psychiatric disorders. 

His lab has made discoveries linking the action of specific stress-related genes with anxiety, depression, social behaviors and metabolism. Prof. Chen and his research team use both mouse genetic models and human patients to ultimately create the scientific groundwork for therapeutic interventions to treat stress-related emotional disorders such as anxiety, post-traumatic stress, anorexia nervosa, and depression.

Ilana Fogelman

Chief executive officer
Share on linkedin

Dr. Fogelman became the CEO of miCure on June 1, 2022. She brings more than 30 years of experience in the development and due diligence of medical technologies (drugs, biologics and in-vitro diagnostics), including regulatory affairs (former FDA medical reviewer), clinical trial design and analysis, market research (former biotech equity analyst), and competitive Intelligence. Co-founder of C2N Diagnostics, a private company developing treatments and diagnostics for Alzheimer’s Disease (C2N launched the PrecivityADTM test, a blood test to aid in the diagnosis of Alzheimer’s). As the COO of LifeTech Research, a consulting firm providing fundamental research to financial institutions, she conducted In-depth due diligence of more than 250 disruptive medical technologies across multiple therapeutic areas. Originally from Brazil, where she obtained her MD, followed by five years of training at Harvard where she obtained an MPH and completed two post-doctoral fellowships (in HIV clinical trials and cellular immunology).

Michel Ben Horovitz

Chief Financial Officer
Share on linkedin

Former CFO of RXZ Investimentos, an investment company focused on listed and private equities. Mr. Horovitz was also a founding partner of two Brazilian Hedge Funds; Skopos Administradora de Recursos and VIX Investimentos. Mr. Horovitz holds a B.S. in Metallurgical Engineering from Universidade de São Paulo.

Sharon Manashirov

Head of Science
Share on linkedin

Mr. Manashirov was involved in the original miR-135 related research at Prof. Chen’s lab and has been working in miCure since its foundation. He has over 10 years of research experience in the field of neurobiology and during his M.Sc. and Ph.D. studies at Prof. Chen’s laboratory, his research focused on linking alteration in epigenetic mechanism and psychiatric disorders as well as identifying translatable targets for the clinic. He has been based in Barcelona since 2017.

Andrés Montefeltro

Head of Delivery Platform Technology
Share on linkedin

Andrés is the CEO and co-founder of CUBIQ FOODS (2018-present), a leading Spanish foodtech company. He is also Managing partner of Lingea Management & Consulting firm, supporting companies in Business development and Oligonucleotide delivery program development. 

Before, as CEO, Senior Vice President, Research Head & Founder, of nLife Therapeutics (2006-2018, he has been involved in the development of oligonucleotides as therapeutic agents, published papers in the field of oligonculeotides for CNS therapies and issued the foundational patents. He holds a B.D. in Biotechnology from the Rosario University in Argentina and a PDD-2004 from IESE Business School (Spain).

Ruben Pavia

Staff scientist
Share on linkedin

Advisory
Board

Jesse
Cedarbaum

Scientific consultant

Fabio
Jung

Strategic consultant

Jose Roberto
Ferraz

Board observer

Jesse Cedarbaum

Scientific consultant
Share on linkedin

Served as Vice President, Movement and Neuromuscular Disorders Clinical Development at Biogen Idec between 2014-2019. Prior to joining Biogen, Dr. Cedarbaum was Vice President, Global Clinical Development for Neuroscience at Bristol-Myers Squibb, where he was responsible for late-stage programs in neurology and psychiatry. 

He has also held senior clinical development positions at Cytokinetics, Elan and Regeneron.

Fabio Jung

Strategic consultant
Share on linkedin

Mr. Fabio Jung graduated a medical school in the Federal University of Rio Grande do Sul
Post Doctoral Fellow at The University of Texas MD Anderson Cancer Center
MBA in Finance and Health Care Management from the Wharton School, University of Pennsylvania
Founding Partner, One Partners

Jose Roberto Ferraz

Board observer
Share on linkedin

J.R. Ferraz has 32 years of international experience in the healthcare industry leading organizations in a variety of segments such as Surgery, Specialty Pharma, E-commerce and retail OTC. He has held senior executive positions at Livanova plc, Nestle Health and Johnson & Johnson and had board experiences in Brazil and Internationally.

Mr. Ferraz holds bachelor’s degree in Business Administration and post graduated in International Marketing and Finance, with both honors being from Fundação Getulio Vargas (FGV).

Board of Directors

Roberto
Ruhman

Chairman of the Board

Bernardo
Parnes

Board Member

Marcelo Bandeira
de Mello

Board Member

Roberto Ruhman

Chairman of the Board
Share on linkedin

Roberto Ruhman is Brazilian, currently living in London, and has a professional career of more than 35 years of experience in financial markets, investment banking and asset management sectors, both as an executive and as an entrepreneur. He graduated from business school (Escola de Administração de Empresas de São Paulo – Fundação Getúlio Vargas).

His career began at Citibank N.A. Brasil, and he worked at Banco Safra S/A. In both institutions, he was a senior bank executive in two different stints.
Roberto started his entrepreneurial activity when he founded Indosuez Capital Emerging Markets. He later joined Banco Matrix S/A as a partner. Roberto next went on to found RXZ Investimentos Ltda., an investment company. Additionally, between 2013-17, Roberto was a member of J. Rothschild Capital Management Limited’s Board of Directors. Currently, he is a founding partner of Joatinga Advisory UK Ltd, along with being the Chairman of the Board of miCure Therapeutics Ltd (an Israeli biotech start-up).

Bernardo Parnes

Board Member
Share on linkedin

Bernardo Parnes, founding partner of Investment One Partners, has more than 30 years of experience leading renowned Brazilian and Global financial institutions. He was CEO for Latin America at Deutsche Bank and Chief Country Officer for Brazil. 

He structured Banco Bradesco BBI S/A, and managed JSI Investimentos Ltda., Joseph Safra’s family office. He was president of Merrill Lynch Brazil for more than 10 years, having started his career in finance at Citibank, where he worked for 7 years.

Marcelo Bandeira de Mello

Board Member
Share on linkedin

Former partner and manager of Banco Matrix S.A., where he worked for eight years. Lawyer and partner of law firms for more than ten years, performing in corporate and tax areas, capital markets and estate planning. 

Graduated from Pontifícia Universidade Católicade São Paulo (PUC/SP), in 1987, with a J.D.